RMTG’s Cellgenic launches NK cell product line for Latin America, Southeast Asia markets

Regenerative Medical Technology Group launched an NK cell product line via Cellgenic for permitted markets outside the US.

• Initial commercial focus targets Latin America and Southeast Asia to capture rising international demand for advanced cellular-technology offerings.
• The move broadens the portfolio into immunology-adjacent categories, supporting cross-selling to physicians and clinics under local regulatory frameworks.
• The strategy aims to turn existing sourcing and manufacturing capabilities into near-term revenue without building new facilities, improving capital efficiency.